Trade Summary

2 days ago, Stengone Carmine N., serving as CEO and President at Contineum Therapeutics, Inc. (CTNM), sold 2,500 shares at $16.00 per share, for a total transaction value of $40,000.00. Following this transaction, Stengone Carmine N. now holds 17,217 shares of CTNM.

This sale represents a 12.68% decrease in Stengone Carmine N.'s stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Wednesday, July 8, 2026 and publicly disclosed via SEC Form 4 filing on Wednesday, July 8, 2026 at 6:49 PM ET, meaning the disclosure happened on the same day as the trade.

Contineum Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.